Diclofenac in the management of E. coli urinary tract infections

Kaushiki Mazumdar, Naton Kumar Dutta, Sujata G. Dastidar, Noboru Motohashi, Yoshiaki Shirataki

Research output: Contribution to journalArticlepeer-review

Abstract

E. coli is the main agent of uncomplicated urinary tract infections (UTIs) and accounts for more than 85% of recurrent cystitis and at least 35% of recurrent pyelonephritis. Despite the widespread availability of antibiotics, UTIs remain the most common bacterial infection in the human population. It is currently advised that the clinical administration of antibiotics against the pathogenic bacteria should be prohibitted due to the emergence of multidrug resistant (MDR) bacterial strains. Therefore, newer and more effective antimicrobials are in demand to treat such cases. One hundred and thirty six urine samples were collected from UTI patients. E. coli was isolated from 85 samples, out of which 33% were resistant to common antibiotics. The isolates were decreasingly resistant to ampicillin, tobramycin, augmentin, nalidixic acid, cefuroxime, nitrofurantoin, kanamycin, pipemidic acid, chloramphenicol, cefotaxime, cefamendol, ofloxacin, ceftizoxime, norfloxacin and amikacin. The anti-inflammatory drug diclofenac exhibited significant antibacterial activity against common bacterial strains both in vitro and in vivo. The present work was conducted to evaluate the in vitro inhibitory effect of this drug on the clinically isolated strains of E. coli in hospitals. All the isolates were sensitive to diclofenac, with MIC values ranging from 5-50, μg/mL. The MIC90 value of the drug was 25 μg/mL. Therefore, it may be suggested that diclofenac has the capacity to treat UTI caused by E. coli.

Original languageEnglish (US)
Pages (from-to)613-620
Number of pages8
JournalIn Vivo
Volume20
Issue number5
StatePublished - Sep 1 2006
Externally publishedYes

Keywords

  • Diclofenac
  • E. coli
  • Urinary tract infections

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Fingerprint Dive into the research topics of 'Diclofenac in the management of E. coli urinary tract infections'. Together they form a unique fingerprint.

Cite this